- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02339649
Long-term Cognitive and Cerebral Changes in Sepsis Survivors and Their Predictors (BonSEP)
Study Overview
Status
Detailed Description
Comparison of cognitive function in severe septic/septic shock ICU patients with non-septic postoperative ICU patients and actively recruited healthy controls at several time points up to 12 months after leaving the ICU.
Secondary aims:
- Profiling specific cognitive deficits in sepsis survivors over time.
- Identifying possible subclasses of long-term cognitive impairment according to facets of disease, therapy and ICU experience.
- Investigating long-term brain morphological changes, with hippocampus as region of interest (ROI).
- Determining values of Serum- and CSF-Biomarkers
- Evaluation of diagnostic and prognostic value of non-routine biomarkers for systemic- and neuroinflammation in the acute phase and in the long-term
- Investigate associations between brain morphological changes, cognitive changes, neurological status, psychiatric burden, disability level, employment status and health-related quality of life (HRQOL).
- Investigating brain-activity changes in resting state electro-encephalogram (EEG)
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Rhine-Westphalia (NRW)
-
Bonn, North Rhine-Westphalia (NRW), Germany, 53105
- Recruiting
- Department of Anesthesiology, University Hospital Bonn
-
-
Northrhine-Westphalia
-
Bonn, Northrhine-Westphalia, Germany, 53117
- Not yet recruiting
- DZNE Center for Clinical Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
INCLUSION CRITERIA:
sepsis/septic shock subjects will only be included in the study if they meet all of the following criteria:
- Written informed consent of the subject. or legal representative patient at the Anesthesiological-Operative Intensive Care Unit of the University Hospital Bonn, the Department of Anesthesiology, Intensive Care and Pain Therapy of the Malteser Hospital, or the Department of Anesthesiology, Intensive Care Medicine and Pain Medicine of the Gemeinschaftskrankenhaus Bonn St. Petrus Hospital. At the Anesthesiological-Operative Intensive Care Unit of the University Hospital Bonn, only, or 1) documentation of presumed will via a relative or legal representative . together with 2) Documentation of verification by a doctor independent of the study that the patient's study participation is unobjectionable. Written informed consent of patient will be obtained at the earliest time possible.
- Aged 25-80 years
- Male or female
- Admitted to the intensive care units of the Anesthesiological-Operative Intensive Care Unit of the University Hospital Bonn, from the Department of Anesthesiology, Intensive Care and Pain Therapy of the Malteser Hospital or from the Department of Anesthesiology, Intensive Care Medicine and Pain Medicine of the Gemeinschaftskrankenhaus Bonn St. Petrus Hospital.
- Duration of ICU stay must be a minimum of 24 hours. In case of transfer to intermediate care or the observation ward before the 24 hour ICU period is complete, study parameters must be allowed to be assessed.
- Fulfill the criteria of sepsis and/or septic shock patients according to theThird International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3, Singer et al, 2016).
Postoperative ICU Patients will only be included in the study if they meet all of the following criteria:
- Written informed consent of the subject.
- Aged 25-80 years
- Male or female
- Admitted to the intensive care units of the Anesthesiological-Operative Intensive Care Unit of the University Hospital Bonn, which includes a surgical ICU, an anesthesiological ICU, and a cardio-surgical ICU
- Duration of ICU stay must be a minimum of 24 hours. In case of transfer to intermediate care or the observation ward before the 24 hour ICU period is complete, study parameters must be allowed to be assessed.
- Mini-Mental Status Examination (MMSE) Score of 25 or above
Healthy Controls will only be included in the study if they meet all of the following criteria:
- Written informed consent of the subject
- Aged 25-80 years
- Male or female
EXCLUSION CRITERIA:
Subjects presenting with any of the following exclusion criteria may not be included in the study:
- Simultaneous participation in any clinical treatment study involving administration of an investigational medicinal product within 30 days prior to study beginning
- Physical or psychiatric condition which at the investigator's discretion may put the subject at risk, may confound the study results, or may interfere with the subject's participation in this study
- Prior to the start of this study existence of preexisting severe diseases and/or conduction of surgery necessarily imply life expectancy less than 12 months
- Known or suspected persistent abuse of medication, drugs or alcohol now or in the past
- Known cerebral lesions, cerebral infarction or malignomas
- Dementia or history of other central nervous system diseases
- Cranial-cerebral injury
- Known HIV-Infection
- Known liver cirrhosis with a documented Child-Pugh Score of C prior to this study
- Liver transplants
- Prior to start of this study nursing care level of 2 or 3
- Prior to start of this study residing in a nursing home
Additional Exclusion Criteria For Non-Septic Postoperative ICU Patients:
- Fulfill the criteria of sepsis and/or septic shock patients according to theThird International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3, Singer et al, 2016).
- In the case that a postoperative ICU patient fulfills the criteria for sepsis during ICU stay, he/she will be moved to the sepsis group.
Additional Exclusion Criteria For Healthy:
- Executing third-party cognitive and functional assessments of another patient-subject also included in this investigation
- History of ICU stay in the last 12 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Sepsis/septic Shock
Men and women seen at the intensive care units of the Anesthesiology Department of the University Hospital Bonn aged 25-80; fulfill the criteria of sepsis and/or septic shock patients according to theThird International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3, Singer et al, 2016). Interventions: Neurocognitive Assessment, Clinical Scales, Questionnaires, Blood Sample, voluntary Lumbar Puncture, Resting State EEG, MRI |
Blood Sample
Neurocognitive Assessment
10-20 Minutes of Resting State EEG
Other Names:
Lumbar Puncture
60 Minutes MRI
|
|
Other: Postoperative ICU Patients
Men and women seen at the intensive care units of the Anesthesiology Department of the University Hospital Bonn aged 25-80:
Interventions: Neurocognitive Assessment, Clinical Scales, Questionnaires, Blood Sample, voluntary Lumbar Puncture, Resting State EEG, MRI |
Blood Sample
Neurocognitive Assessment
10-20 Minutes of Resting State EEG
Other Names:
Lumbar Puncture
60 Minutes MRI
|
|
Other: Healthy Controls
Healthy Controls will only be included in the study if they meet all of the following criteria: Written informed consent of the subject, Aged 25-80 years, Male or female. Interventions: Neurocognitive Assessment, Clinical Scales, Questionnaires, Blood Sample, voluntary Lumbar Puncture, Resting State EEG, MRI |
Blood Sample
Neurocognitive Assessment
10-20 Minutes of Resting State EEG
Other Names:
Lumbar Puncture
60 Minutes MRI
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Verbal Learning Memory Test Long Delayed Recall (Trial 7)
Time Frame: 6 months post ICU
|
Verbal Learning Memory Test Long Delayed Recall (Trial 7) at 6 months post ICU admission in sepsis/septic shock patients versus non-septic postoperative patients, and comparison to actively recruited healthy controls)
|
6 months post ICU
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Verbal Learning Memory Test, German Version
Time Frame: For patient groups: 6 months; for Healthy Controls: Baseline
|
Verbal Learning and Memory: Verbal Learning Memory Test, German Version
|
For patient groups: 6 months; for Healthy Controls: Baseline
|
|
Verbal Learning Memory Test, German Version
Time Frame: For patient groups: 12 months; for Healthy Controls: 6 months
|
Verbal Learning and Memory: Verbal Learning Memory Test, German Version
|
For patient groups: 12 months; for Healthy Controls: 6 months
|
|
Wechsler Memory Scale IV Visual Recall I and II
Time Frame: For patient groups: 6 months; for Healthy Controls: Baseline
|
Visual Memory: Wechsler Memory Scale IV Visual Recall I and II
|
For patient groups: 6 months; for Healthy Controls: Baseline
|
|
Wechsler Memory Scale IV Visual Recall I and II
Time Frame: For patient groups: 12 months; for Healthy Controls: 6 months
|
Visual Memory: Wechsler Memory Scale IV Visual Recall I and II
|
For patient groups: 12 months; for Healthy Controls: 6 months
|
|
Wechsler Memory Scale Digit-Span
Time Frame: For patient groups: 6 months; for Healthy Controls: Baseline
|
Working Memory: Wechsler Memory Scale Digit-Span
|
For patient groups: 6 months; for Healthy Controls: Baseline
|
|
Wechsler Memory Scale Digit-Span
Time Frame: For patient groups: 12 months; for Healthy Controls: 6 months
|
Working Memory: Wechsler Memory Scale Digit-Span
|
For patient groups: 12 months; for Healthy Controls: 6 months
|
|
German Vocabulary Test
Time Frame: For patient groups: 6 months; for Healthy Controls: Baseline
|
Premorbid Verbal Ability: German Vocabulary Test Mehrfachwahl Wortschatztest B (MWT-B)
|
For patient groups: 6 months; for Healthy Controls: Baseline
|
|
German Vocabulary Test
Time Frame: For patient groups: 12 months; for Healthy Controls: 6 months
|
Premorbid Verbal Ability: German Vocabulary Test
|
For patient groups: 12 months; for Healthy Controls: 6 months
|
|
Symbol Digit Modalities Test
Time Frame: For patient groups: 6 months; for Healthy Controls: Baseline
|
Cognitive Speed
|
For patient groups: 6 months; for Healthy Controls: Baseline
|
|
Symbol Digit Modalities Test
Time Frame: For patient groups: 12 months; for Healthy Controls: 6 months
|
Cognitive Speed
|
For patient groups: 12 months; for Healthy Controls: 6 months
|
|
Trail Making Test A & B
Time Frame: For patient groups: 6 months; for Healthy Controls: Baseline
|
Simple and Divided Attention
|
For patient groups: 6 months; for Healthy Controls: Baseline
|
|
Trail Making Test A & B
Time Frame: For patient groups: 12 months; for Healthy Controls: 6 months
|
Simple and Divided Attention
|
For patient groups: 12 months; for Healthy Controls: 6 months
|
|
Phonetic and Lexical Verbal Fluency
Time Frame: For patient groups: 6 months; for Healthy Controls: Baseline
|
Phonetic and Lexical Verbal Fluency
|
For patient groups: 6 months; for Healthy Controls: Baseline
|
|
Phonetic and Lexical Verbal Fluency
Time Frame: For patient groups: 12 months; for Healthy Controls: 6 months
|
Phonetic and Lexical Verbal Fluency
|
For patient groups: 12 months; for Healthy Controls: 6 months
|
|
Patient Health Questionnaire Subtests Depression, Anxiety and Somatic Symptoms
Time Frame: For patient groups: 6 months; for Healthy Controls: Baseline
|
Depression and Anxiety Inventory
|
For patient groups: 6 months; for Healthy Controls: Baseline
|
|
Patient Health Questionnaire Subtests Depression, Anxiety and Somatic Symptoms
Time Frame: For patient groups: 12 months; for Healthy Controls: 6 months
|
Depression and Anxiety Inventory
|
For patient groups: 12 months; for Healthy Controls: 6 months
|
|
Post-Traumatic Stress Syndrome 10
Time Frame: For patient groups: 6 months; for Healthy Controls: Baseline
|
Post-Traumatic Stress Screening
|
For patient groups: 6 months; for Healthy Controls: Baseline
|
|
Post-Traumatic Stress Syndrome 10
Time Frame: For patient groups: 12 months; for Healthy Controls: 6 months
|
Post-Traumatic Stress Screening
|
For patient groups: 12 months; for Healthy Controls: 6 months
|
|
European Quality of Life 5 Dimensions-5 Levels
Time Frame: For patient groups: 6 months; for Healthy Controls: Baseline
|
Quality of Life
|
For patient groups: 6 months; for Healthy Controls: Baseline
|
|
European Quality of Life 5 Dimensions-5 Levels
Time Frame: For patient groups: 12 months; for Healthy Controls: 6 months
|
Quality of Life
|
For patient groups: 12 months; for Healthy Controls: 6 months
|
|
Functional Activities Questionnaire
Time Frame: For patient groups: 6 months; for Healthy Controls: Baseline
|
Activities of Daily Living
|
For patient groups: 6 months; for Healthy Controls: Baseline
|
|
Functional Activities Questionnaire
Time Frame: For patient groups: 12 months; for Healthy Controls: 6 months
|
Activities of Daily Living
|
For patient groups: 12 months; for Healthy Controls: 6 months
|
|
modified version of Rankin Scale Structured Interview (modified for ICU patients)
Time Frame: For patient groups: 6 months; for Healthy Controls: Baseline
|
Function Scale
|
For patient groups: 6 months; for Healthy Controls: Baseline
|
|
modified version of Rankin Scale Structured Interview (modified for ICU patients)
Time Frame: For patient groups: 12 months; for Healthy Controls: 6 months
|
Function Scale
|
For patient groups: 12 months; for Healthy Controls: 6 months
|
|
Pittsburgh Sleep Quality Index
Time Frame: For patient groups: 6 months; for Healthy Controls: Baseline
|
Sleep Quality
|
For patient groups: 6 months; for Healthy Controls: Baseline
|
|
Pittsburgh Sleep Quality Index
Time Frame: For patient groups: 12 months; for Healthy Controls: 6 months
|
Sleep Quality
|
For patient groups: 12 months; for Healthy Controls: 6 months
|
|
Mini Mental Status Examination
Time Frame: For patient groups: (OP Probands 1-28 d before OP, 6 months; for Healthy Controls: Baseline
|
Cognitive Screening
|
For patient groups: (OP Probands 1-28 d before OP, 6 months; for Healthy Controls: Baseline
|
|
Mini Mental Status Examination
Time Frame: For patient groups: 12 months; for Healthy Controls: 6 months
|
Cognitive Screening
|
For patient groups: 12 months; for Healthy Controls: 6 months
|
|
Clinical Scales at ICU
Time Frame: For Patients during ICU Stay (Day 0, [Day 7 if still on ICU], Day of Release)
|
Therapeutic Intervention Scoring System-10, Total Score Simplified Acute Physiology Score, Sequential Organ Failure Assessment Confusion Assessment Method for the ICU
|
For Patients during ICU Stay (Day 0, [Day 7 if still on ICU], Day of Release)
|
|
Neurological Examination
Time Frame: For patient groups: 6 months, 12 months; for Healthy Controls: Baseline and 6 months
|
Subscales Motor ability, Walking and Standing, Behavior, Praxis/Visual or Visuospatial, Speaking and Language, Autonomic Nervous System, Tone and Muscle Exam, Coordination and Movement
|
For patient groups: 6 months, 12 months; for Healthy Controls: Baseline and 6 months
|
|
resting state electroencephalogram
Time Frame: For patient groups: 6 months, 12 months; for Healthy Controls: Baseline and 6 months
|
10-20 system electroencephalogram (64 channels with additional electro-oculogram, electromyogram, electrocardiogram).
The protocol includes 5 phases, each one minute long: 1) eyes open, relaxed state, fixation of a black dot at 2 m distance, 2) word generation using letter "P" with eyes closed, 3) mental arithmetic: continuous subtraction of 7 starting from 1,000 with eyes closed, 4) eyes closed, relaxed state, no task, 5) visualization of a previously memorized geometric figure with eyes closed.
Data sampled at a rate of 256 Herz using an anti-aliasing low pass filter.
Power spectra will be calculated for consecutive 4-second windows and calculated for each electrode contact.
Absolute spectral power will be determined for the delta (0.5-4 Herz), theta (4-8 Herz), alpha (8-13 Herz), beta (13-20 Herz) and gamma (20-40 Herz) bands, which will be averaged across all windows.
|
For patient groups: 6 months, 12 months; for Healthy Controls: Baseline and 6 months
|
|
MRI (3 Tesla) of brain with hippocampus as Region of Interest
Time Frame: For patient groups: 6 months, 12 months; for Healthy Controls: Baseline and 6 months
|
MRI (3 Tesla) of brain with hippocampus as Region of Interest.
Protocol includes: three-dimensional, T1-weighted rapid gradient echo sequence, Resting State, Gradient Echo-Field-Map for Resting State, Inversion Recovery Echo Planar Imaging for Resting State, Spoiled Gradient Echo, Fluid Attenuated inversion Recovery, Susceptibility weighted imaging, Diffusion Tensor Imaging, Gradient Echo-Field-Map for Diffusion Tensor Imaging
|
For patient groups: 6 months, 12 months; for Healthy Controls: Baseline and 6 months
|
|
Blood Sample
Time Frame: For Patient Groups 2-3 samples during ICU, 3-4 Months, 6 months, 12 Months
|
All blood samples shall be drawn, stored and analyzed according to the participant information in the laboratories of the Biomarker Dementia Working Group and the Central Laboratory.
Blood sampling analysis will include leukocyte count, hemoglobin, hematocrit, erythrocytes, Mean Corpuscular Hemoglobin, Meam Corpuscular Volume, mean Corpuscular Hemoglobin Concentration, Thrombocytes, Glucose, Lactate, electrolytes Sodium, Potassium, Calcium, Cholesterine, Tumor necrosis Factor-alpha, Interleukin-1 alpha, Interleukin-1 beta, Interleukin-6, C-reactive protein, Neuron Specific Enolase, Procalcitonin, S-100 Protein, as well as DNA and serum biorepository for further scientific analysis.
|
For Patient Groups 2-3 samples during ICU, 3-4 Months, 6 months, 12 Months
|
|
Lumbar Puncture (voluntary)
Time Frame: For Patients: (while at ICU, if clinically indicated as part of clinical routine and only if patient directly gives informed consent), 12 months; For Healthy Controls: Baseline and 6 months
|
Cerebrospinal fluid (CSF) routine parameters will be analyzed by the Central Laboratory.
Results will then be provided to the investigator.
For determination of τ, phospho-τ, β-amyloid 1 40 and β-amyloid 1 42, 5 ml of cerebral-spinal-fluid will be analyzed at the laboratories of the German Center for Neurodegenerative Diseases (DZNE), Biomarker Dementia Working Group, Sigmund-Freud-Str.
25, 53105 Bonn
|
For Patients: (while at ICU, if clinically indicated as part of clinical routine and only if patient directly gives informed consent), 12 months; For Healthy Controls: Baseline and 6 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Michael T Heneka, M.D., German Center for Neurodegenerative Diseases (DZNE)
- Study Chair: Andreas Hoeft, M.D., Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn
- Study Chair: Christian Putensen, M.D., Research Unit Pulmonary Dysfunction and Sepsis, Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn
- Study Chair: Thomas Klockgether, M.D., German Center for Neurodegenerative Diseases (DZNE)
Publications and helpful links
General Publications
- Pandharipande PP, Girard TD, Jackson JC, Morandi A, Thompson JL, Pun BT, Brummel NE, Hughes CG, Vasilevskis EE, Shintani AK, Moons KG, Geevarghese SK, Canonico A, Hopkins RO, Bernard GR, Dittus RS, Ely EW; BRAIN-ICU Study Investigators. Long-term cognitive impairment after critical illness. N Engl J Med. 2013 Oct 3;369(14):1306-16. doi: 10.1056/NEJMoa1301372.
- Iwashyna TJ, Ely EW, Smith DM, Langa KM. Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA. 2010 Oct 27;304(16):1787-94. doi: 10.1001/jama.2010.1553.
- Sonneville R, Verdonk F, Rauturier C, Klein IF, Wolff M, Annane D, Chretien F, Sharshar T. Understanding brain dysfunction in sepsis. Ann Intensive Care. 2013 May 29;3(1):15. doi: 10.1186/2110-5820-3-15.
- Weberpals M, Hermes M, Hermann S, Kummer MP, Terwel D, Semmler A, Berger M, Schafers M, Heneka MT. NOS2 gene deficiency protects from sepsis-induced long-term cognitive deficits. J Neurosci. 2009 Nov 11;29(45):14177-84. doi: 10.1523/JNEUROSCI.3238-09.2009.
- Semmler A, Widmann CN, Okulla T, Urbach H, Kaiser M, Widman G, Mormann F, Weide J, Fliessbach K, Hoeft A, Jessen F, Putensen C, Heneka MT. Persistent cognitive impairment, hippocampal atrophy and EEG changes in sepsis survivors. J Neurol Neurosurg Psychiatry. 2013 Jan;84(1):62-9. doi: 10.1136/jnnp-2012-302883. Epub 2012 Nov 7.
- Widmann CN, Heneka MT. Long-term cerebral consequences of sepsis. Lancet Neurol. 2014 Jun;13(6):630-6. doi: 10.1016/S1474-4422(14)70017-1.
- Widmann CN, Schewe JC, Heneka MT. Sepsis-associated encephalopathy versus sepsis-induced encephalopathy--authors' reply. Lancet Neurol. 2014 Oct;13(10):968-9. doi: 10.1016/S1474-4422(14)70204-2. No abstract available.
- Lindlau A, Widmann CN, Putensen C, Jessen F, Semmler A, Heneka MT. Predictors of hippocampal atrophy in critically ill patients. Eur J Neurol. 2015 Feb;22(2):410-5. doi: 10.1111/ene.12443. Epub 2014 Apr 12.
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BN005
- 2011-003014-16 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Severe Sepsis With Septic Shock
-
Indonesia UniversityCompletedSevere Sepsis With Septic Shock | Severe Sepsis Without Septic ShockIndonesia
-
Klinikum EmdenUniversitätsklinikum Hamburg-Eppendorf; Kantonsspital Baden; Kantonsspital MünsterlingenCompleted
-
Peking Union Medical College HospitalUnknownLactate | Severe Sepsis With Septic Shock
-
University of UtahNational Institutes of Health (NIH)CompletedSevere Sepsis With Septic Shock
-
University of California, San FranciscoNational Cancer Institute (NCI)RecruitingSepsis | Sepsis, Severe | Sepsis and Septic Shock | Sepsis at Intensive Care Unit | Sepsis, Septic Shock | Sepsis, Severe Sepsis and Septic Shock | Sepsis With Multiple Organ Dysfunction (MOD) | Sepsis With Acute Organ DysfunctionUnited States
-
Yonsei UniversityCompletedSevere Sepsis or Septic ShockKorea, Republic of
-
University of RostockCompletedSevere Sepsis and Septic ShockGermany
-
University Hospital, Strasbourg, FranceUnknownSevere Sepsis and Septic ShockFrance
-
Australian and New Zealand Intensive Care Research...University of Pittsburgh; Intensive Care National Audit & Research CentreCompleted
-
International Centre for Diarrhoeal Disease Research...RecruitingLactate Blood Increase | Severe Sepsis With Septic ShockBangladesh
Clinical Trials on Blood Sample
-
Institut PasteurCentre Terrritorial Hospitalier Gaston BourretNot yet recruiting
-
First Affiliated Hospital of Zhejiang UniversityRecruitingComplication | Hematologic Malignancy | Hematopoietic Stem Cell Transplantation | Chronic Graft-versus-host-diseaseChina
-
University Hospital, BordeauxMinistry for Health and Solidarity, FranceRecruitingImmune Thrombocytopenia | Autoimmune Hemolytic Anemia | Autoimmune NeutropeniaFrance
-
University Hospital, ToursCompletedMetastatic Prostate Cancer | Circulating Tumor DNAFrance
-
University Hospital, BordeauxCompletedRenal Function Disorder | Chronic Renal Diseases
-
Medical University of WarsawCompletedArthroplasty | Platelet Aggregation | Methylmethacrylate EmbolismPoland
-
Stanford UniversityWithdrawnNeuroendocrine Tumors | Carcinoid TumorUnited States
-
Masonic Cancer Center, University of MinnesotaCompletedAcute Myeloid LeukemiaUnited States
-
The First Affiliated Hospital of Soochow UniversityRecruitingGraft Vs Host DiseaseChina
-
Meir Medical CenterCompleted